RxDoctor Payments Data

Kevin Steel, DO

Cardiovascular Disease · Bellingham, WANPI 1578624979

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,802 of the $11,795 with a category attached, or 66.1%. 12 manufacturers reported payments, led by Circle Cardiovascular Imaging Inc. at 31.8% of the total. Reporting peaked in 2022 at $5,724 and has fallen 94.4% since, to $322 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,795in general payments, 2019–2025

Across 33 payments — averaging $357.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Circle Cardiovascular Imaging Inc.$4K
  • Bayer$3K
  • Boston Scientific$2K
  • Abbott$1K
  • Medtronic$740
  • Heartflow, Inc.$349
  • plus $272 from 6 others

What the payments were for

  • Consulting fees$7,80266%
  • Travel & lodging$2,50221%
  • Food & beverage$1,49113%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,795 in reported general payments places this provider in the 90th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$241,048
Medicare patients
2,377
Services billed
8,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban201$231,642
XareltoRivaroxaban70$71,618
EntrestoSacubitril/Valsartan23$37,539
JardianceEmpagliflozin13$19,083
Repatha SureclickEvolocumab22$18,857
Metoprolol Succinate250$4,794
Potassium Chloride78$1,931
Carvedilol112$1,919
Atorvastatin Calcium74$1,855
ClopidogrelClopidogrel Bisulfate59$1,807
Flecainide Acetate38$1,798
Losartan Potassium103$1,188
Lisinopril73$1,012
Metoprolol Tartrate96$821
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$23$71,61870 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →